2017 World Retrovirus Conference invites Ezeibe to Canada

As mixed reactions greet the recent cure-medicine for HIV/AIDS invented by Prof. Maduike Ezeibe of Micheal Okpara University of Agriculture Umudike, Abia state, MOUAU, the 2017 and 3rd International Conference On “Retroviruses and Novel Drugs” has invited the professor of Veterinary Medicine to present a paper at the conference scheduled for July 27 – 28 in Vancouver, Canada.

The invitation to the conference, according to the Programme Manager of the Retroviruses – 2017 Conference Series, Dr. Samantha Olivia, followed the acceptance of the Abstract of professor Ezeibe’s intended paper after its review by the Review Committee.

His paper’s Abstract titled “Responses of patients at different stages of HIV-infection, to treatment with Medicinal synthetic Aluminum-magnesium silicate`s {Al4 (SiO4) 3 + 3Mg2SiO4 → 2Al2Mg3(SiO4) 3} ” reads: “Small size of viruses allows them access to organs that are in-access-able to medicines (big molecules). When patients are treated, immunity clears such infections but for infections that cause immune-deficiency, there would be nothing to clear them.

“Affected organs become “sanctuary” for the infections. Aluminum silicate and Magnesium silicate were reacted {Al4 (SiO4) 3 + 3Mg2SiO4→2Al2Mg3(SiO4) 3} for medicinal synthetic Aluminum-magnesium silicate (MSAMS, Antivirt®). Molecules of MSAMS are made of Nanoparticles with positive and negative electrically charged ends.

“Ultra small size of MSAMS-Nanoparticles allows them access to all organs. They bond their ends to opposite charges, on viruses and infected cells. MSAMS also elicits lymphocytosis.

“Synergy between its antiviral effects and the lymphocytosis terminates viral infections. HIV-infected persons were classified as: (i) HIV-positive patients (CD4 ≥500) and (ii) HIV/AIDS patients (CD4 <500). Each patient was treated, daily, with Antivirt® (50mg/kg) and immunace extra-protection® (1 tablet).

“They were tested before the treatment and every month, for viral loads and CD4 counts. Mean CD4 counts of the HIV-positive patients (663.60±45.43) was more (P=0.00) than that of the HIV/AIDS patients (330.00±32.01) but means of their monthly CD4 before they recovered (1461.78±339.84 and 1400.00±301.30) became approximately same (P=0.89).

“HIV antigens and antibodies regressed, completely, in HIV-positive patients after 8.40±0.24 months while it took 10.00 ±0.00 months before HIV/AIDS patients recovered (P=0.00).

“Symptoms were observed in HIV/AIDS patients but the HIV-positives remained apparently healthy. Conclusion is that both patients at HIV-positive stage and those at HIV/AIDS stage can recover, if treated with Antivirt®-immune stimulants regimen.”

Ezeibe told The Guardian that his paper’s Abstract concluded that his invented Medicine can cure both patients who are just HIV -Positive and those who have AIDS, pointing out that “acceptance of the paper means that the world has accepted that Nigeria now has cure for HIV.”

Ezeibe added that he accepted the Invitation to participate at the said Canada conference to present his paper, noting, “last year, no paper from Nigeria was accepted by the Conference but this year, mine was accepted.”